We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Cyteir Therapeutics Inc | NASDAQ:CYT | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 3.02 | 3.04 | 3.14 | 0 | 01:00:00 |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): |
(Exact name of Registrant as Specified in Its Charter)
(State or Other Jurisdiction |
(Commission File Number) |
(IRS Employer |
||
|
|
|
|
|
|
||||
|
||||
(Address of Principal Executive Offices) |
|
(Zip Code) |
Registrant’s Telephone Number, Including Area Code: |
Not Applicable |
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
|
|
Trading |
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
On March 7, 2024, Cyteir Therapeutics, Inc. (the “Company”) delivered formal notice to The Nasdaq Stock Market that the Company intends to voluntarily delist its common stock, par value $0.001 per share (the “Common Stock”), from the Nasdaq Global Select Market (“Nasdaq”) in connection with the Company’s voluntary Plan of Complete Liquidation and Dissolution previously approved by the Company’s Board of Directors and stockholders.
The Company expects to file a Notification of Removal from Listing and/or Registration on Form 25 with the Securities and Exchange Commission (the “SEC”) on or about March 18, 2024 to effect the voluntary delisting of the Common Stock under Section 12(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and that the delisting will be effective on or about March 28, 2024, ten days after the filing of the Form 25. In connection with the foregoing, the Company requested that the trading of the Common Stock on Nasdaq be suspended effective before the market opens on March 18, 2024. Following the effectiveness of the delisting, the Company intends to file a Form 15 with the SEC to terminate the registration of the Common Stock under Section 12(g) of the Exchange Act, thereby suspending the Company’s Exchange Act reporting obligations.
A copy of the press release announcing the matters summarized above is filed as Exhibit 99.1 hereto and is incorporated herein by reference.
Item 8.01 Other Events
On March 7, 2024, the Company issued a press release regarding the matters disclosed in Item 3.01 above. A copy of the press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
Exhibit No. |
|
Description |
|
|
|
99.1 |
|
Press Release of Cyteir Therapeutics, Inc. dated March 7, 2024 |
104 |
|
Cover Page Interactive Data File (embedded within the inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
|
|
CYTEIR THERAPEUTICS, INC. |
|
|
|
|
Date: |
March 7, 2024 |
By: |
/s/ David Gaiero |
|
|
|
Name: David Gaiero |
Exhibit 99.1
Cyteir Announces Timeline for Voluntarily Delisting from Nasdaq
LEXINGTON, MA— March 7, 2024 — Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT) today announced that it has formally notified The Nasdaq Stock Market (“Nasdaq”) of its intent to delist the Company’s common stock from the Nasdaq Global Select Market. Cyteir expects to file a Form 25 (Notification of Removal from Listing) with the Securities and Exchange Commission (the “SEC”) relating to the voluntary delisting of its common stock on or about March 18, 2024 and has requested that the trading of the Common Stock on Nasdaq be suspended effective before the market opens on the same day. Cyteir does not expect that a trading market will develop for its common stock following suspension of trading on Nasdaq. Cyteir intends to file a certificate of dissolution with the Delaware Secretary of State on or about March 20, 2024 and close its stock transfer books at the close of business on this date. The official delisting of Cyteir’s common stock will be effective on or about March 28, 2024, ten days after the filing of the Form 25.
Cyteir also intends to file a Form 15 with the SEC as soon as practicable following the effectiveness of the delisting to indefinitely suspend its reporting obligations under the Securities Exchange Act of 1934, as amended.
The voluntary delisting and deregistration are part of Cyteir’s Plan of Complete Liquidation and Dissolution previously approved by Cyteir’s board of directors and by Cyteir’s stockholders at a special meeting held on November 16, 2023. Cyteir’s board of directors considered a number of factors in determining to delist and deregister its common stock, including the costs and expenses associated with being a publicly traded company, the auditing, legal and other costs associated with continuing to make SEC filings, and the burdens placed on Cyteir’s management to comply with the continued listing and reporting requirements, all in light of Cyteir’s planned dissolution and liquidation.
Forward-Looking Statements
This press release contains “forward-looking statements,” including with respect to the timing of Cyteir’s planned dissolution and liquidation. The words ”believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “could,” “target,” “predict,” “seek” and similar expressions are intended to identify forward-looking statements. All statements other than statements of historical facts contained in this press release are forward-looking statements.
These forward-looking statements are subject to a number of risks, uncertainties and assumptions, which could cause actual results to differ materially from those contained in or implied by the forward-looking statements, including the risks and uncertainties identified under the heading “Risk Factors” in Cyteir’s definitive proxy statement filed with the Securities and Exchange Commission on October 12, 2023.
The forward-looking statements contained in this press release are based on management's current views, plans, estimates, assumptions, and projections with respect to future events, and, except to the extent required by law, Cyteir does not undertake and specifically disclaims any obligation to update any forward-looking statements.
Document and Entity Information |
Mar. 07, 2024 |
---|---|
Cover [Abstract] | |
Amendment Flag | false |
Entity Central Index Key | 0001662244 |
Document Type | 8-K |
Document Period End Date | Mar. 07, 2024 |
Entity Registrant Name | Cyteir Therapeutics, Inc. |
Entity Incorporation State Country Code | DE |
Securities Act File Number | 001-40499 |
Entity Tax Identification Number | 45-5429901 |
Entity Address, Address Line One | P.O. Box 80084 |
Entity Address, City or Town | Stoneham |
Entity Address, State or Province | MA |
Entity Address, Postal Zip Code | 02180 |
City Area Code | 857 |
Local Phone Number | 285-4140 |
Written Communications | false |
Soliciting Material | false |
Pre Commencement Tender Offer | false |
Pre Commencement Issuer Tender Offer | false |
Security 12b Title | Common Stock, $0.001 par value per share |
Trading Symbol | CYT |
Security Exchange Name | NASDAQ |
Entity Emerging Growth Company | true |
Entity Ex Transition Period | false |
1 Year Cyteir Therapeutics Chart |
1 Month Cyteir Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions